Holen Sie sich die Stockscreener-App
4.68
6.40%
-0.32
Handel nachbörslich:
4.67
-0.010
-0.21%
Schlusskurs vom Vortag:
$5.00
Offen:
$5.09
24-Stunden-Volumen:
40,746
Relative Volume:
2.56
Marktkapitalisierung:
$43.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.72M
KGV:
-0.6199
EPS:
-7.5501
Netto-Cashflow:
$-52.35M
1W Leistung:
-2.30%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.58
$5.09
1-Wochen-Bereich:
$4.415
$5.1512
52-Wochen-Spanne:
$4.4001
$6.625
Leonabio Inc Stock (LONA) Company Profile
Firmenname
Leonabio Inc
Sektor
Branche
Telefon
(425) 620-8501
Adresse
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
4.68 | 46.68M | 0 | -37.72M | -52.35M | -7.5501 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-19 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-09-04 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-09-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-10-17 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-06-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | Herabstufung | Jefferies | Buy → Hold |
| 2022-06-23 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Eingeleitet | BTIG Research | Buy |
| 2022-04-21 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Goldman | Neutral |
| 2020-10-13 | Eingeleitet | Goldman | Buy |
| 2020-10-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-13 | Eingeleitet | Jefferies | Buy |
| 2020-10-13 | Eingeleitet | Stifel | Buy |
Alle ansehen
Leonabio Inc Aktie (LONA) Neueste Nachrichten
LeonaBio (ATHA) proxy asks investors to back warrant share issuances and 2026 equity plan - stocktitan.net
LeonaBio appoints Mark Kubik as chief business officer By Investing.com - Investing.com Nigeria
Leonabio, Inc. Announces the Appointment of Mark F. Kubik as Chief Business Officer - marketscreener.com
LeonaBio (LONA) Names Mark Kubik as New Chief Business Officer - GuruFocus
LeonaBio appoints Mark Kubik as chief business officer - Investing.com
LeonaBio, Inc. Appoints Mark F. Kubik as Chief Business Officer to Drive Business Development Strategy - Quiver Quantitative
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer - marketscreener.com
Biopharma deal veteran to drive LeonaBio’s Phase 3 breast cancer drug - Stock Titan
Leonabio Inc files for offering of up to 58.5 million shares of common stock by the selling stockholders - marketscreener.com
Leonabio Inc Files For Offering Of Up To 58.5 Million Shares Of Common Stock By The Selling Stockholders - TradingView
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA" - Investing News Network
Athira Pharma (ATHA) Options to Be Delisted on January 12th - GuruFocus
LONA Stock Price, News & Analysis - Stock Titan
Athira Pharma Rebrands as LeonaBio, Refocusing on Oncology - TipRanks
Athira Pharma announces name change to LeonaBio - TipRanks
Athira Pharma roars into the new year with rebrand to LeonaBio - Fierce Pharma
Athira Pharma changes name, ticker symbol - MSN
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy - Investing.com Nigeria
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy By Investing.com - Investing.com South Africa
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” - Yahoo Finance
New breast cancer drug moves into late testing with $236M funding deal - Stock Titan
Athira Pharma (NASDAQ: ATHA) posts $6.6M Q3 loss; ATH-1105 study shows favorable safety, CNS penetration - Stock Titan
Athira Pharma announces reverse stock split - marketscreener.com
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 - GlobeNewswire
Breakthrough ALS Drug ATH-1105 Achieves Key Safety Milestones, Targets Patient Trials Late 2025 - Stock Titan
Athira Pharma Slides As Insider Purchases Lose Another US$89k - simplywall.st
ATHA Stock Price, News & Analysis - stocktitan.net
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - marketscreener.com
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology - marketscreener.com
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND - marketscreener.com
Athira Pharma, Inc. Plans to Further Extend the Current OLEX for the Phase 2/3 LIFT-AD and Phase 2 ACT-AD Trials - marketscreener.com
Athira Pharma Provides 2023 Pipeline Outlook - marketscreener.com
Goldman Sachs Adjusts Price Target for Athira Pharma to $3 From $11, Maintains Neutral Rating - marketscreener.com
Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates - marketscreener.com
Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth - simplywall.st
Alzheimer’s Disease Stock Cortexyme Craters on Trial Failure - Bloomberg.com
ATHAAthira Pharma, Inc. Latest Stock News & Market Updates - Stock Titan
Finanzdaten der Leonabio Inc-Aktie (LONA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):